SGLT-2 Inhibitors and GLP-1R Agonists Explored for Reducing Coronary Inflammation in Type 2 Diabetes
Exploration of the Effects of SGLT-2 Inhibitors and GLP-1 Receptor Agonists on Coronary Inflammation in Type 2 Diabetes Patients Based on the Peri-Coronary Fat Attenuation Index
Abstract
Study aims to determine if SGLT-2 inhibitors and GLP-1R agonists reduce coronary inflammation in Type 2 Diabetes patients, using peri-coronary fat attenuation index (FAI).